In contrast, we demonstrate that concurrent treatment with STING agonist, anti-PD-1, olaparib and AZD1775 in AT3OVA tumours can overcome anti-PD-1 treatment resistance to result in durable tumour clearance. This evidence concerns the gene PDCD1 and neoplasm.